Galectins in hematological malignancies

Current Opinion in Hematology

Volumn 20, Issue 4, 2013, Pages 327-335

  Giordano, Mirta ^a   Croci, Diego O ^b   Rabinovich, Gabriel A ^b,c  

^a ACADEMIA NACIONAL DE MEDICINA   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Galectins; Hodgkin?s lymphoma; Lymphomas; Myeloma; Non Hodgkin?s lymphoma

Indexed keywords

ECALECTIN; GALECTIN; GALECTIN 1; GALECTIN 10; GALECTIN 11; GALECTIN 12; GALECTIN 13; GALECTIN 14; GALECTIN 15; GALECTIN 2; GALECTIN 3; GALECTIN 4; GALECTIN 5; GALECTIN 6; GALECTIN 7; LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CUTANEOUS T CELL LYMPHOMA; DENDRITIC CELL; DISEASE ASSOCIATION; FOLLICULAR LYMPHOMA; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LYMPH NODE; LYMPHOPROLIFERATIVE DISEASE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SPLEEN; T LYMPHOCYTE; TUMOR INVASION;

GALECTINS; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNITY, CELLULAR; NEOPLASM PROTEINS; T-LYMPHOCYTES;

EID: 84880234937     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e328362370f     Document Type: Review

References (60)

1. Rabinovich GA, Croci DO. Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer. Immunity 2012; 36:322-335.
2. Rabinovich GA, Toscano MA, Jackson SS, Vasta GR. Functions of cell surface galectin-glycoprotein lattices. Curr Opin Struct Biol 2007; 17:513-520.
3. Liu FT, Rabinovich GA. Galectins: regulators of acute and chronic inflammation. Ann N Y Acad Sci 2010; 1183:158-182.
4. Hirabayashi J, Hashidate T, Arata Y, et al. Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochim Biophys Acta 2002; 1572:232-254.
5. Rabinovich GA, Vidal M. Galectins and microenvironmental niches during hematopoiesis. Curr Opin Hematol 2011; 18:443-451.
6. Toscano MA, Bianco GA, Ilarregui JM, et al. Differential glycosylation of Th1, Th2 and Th-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol 2007; 8:825-834.
7. Ilarregui JM, Croci DO, Bianco GA, et al. Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin Nat Immunol 2009; 10:981-991.
8. Starossom SC, Mascanfroni ID, Imitola J, et al. Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration. Immunity 2012; 37:249-263.
9. Dalotto-Moreno T, Croci DO, Cerliani JP, et al. Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease. Cancer Res 2013; 73:1107-1117.
10. Cedeno-Laurent F, Watanabe R, Teague JE, et al. Galectin-1 inhibits the viability, proliferation, and Th1 cytokine production of nonmalignant T cells in patients with leukemic cutaneous T-cell lymphoma. Blood 2012; 119:3534-3538
11. Zhu C, Anderson AC, Schubart A, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005; 6:1245-1252.
12. Anderson DE. TIM-3 as a therapeutic target in human inflammatory diseases. Expert Opin Ther Targets 2007; 11:1005-1009.
13. Ito K, Stannard K, Gabutero E, et al. Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment. Cancer Metastasis Rev 2012; 31:763-778.
14. Rubinstein N, Alvarez M, Zwirner NW, et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; a potential mechanism of tumor-immune privilege. Cancer Cell 2004; 5:241-251.
15. Juszczynski P, Ouyang J, Monti S, et al. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci USA 2007; 104:13134-13139.
16. Banh A, Zhang J, Cao H, et al. Tumor galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis. Cancer Res 2011; 71:4423-4431.
17. Demotte N, Stroobant V, Courtoy PJ, et al. Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Immunity 2008; 28:414-424.
18. Tsuboi S, Sutoh M, Hatakeyama S, et al. A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans. EMBO J 2011; 30:3173-3185.
19. Thijssen VL, Barkan B, Shoji H, et al. Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res 2010; 70:6216-6224.
20. Croci DO, Salatino M, Rubinstein N, et al. Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma. J Exp Med 2012; 209:1985-2000.
21. Laderach DJ, Gentilini LD, Giribaldi L, et al. A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease. Cancer Res 2013; 73:86-96.
22. Markowska AI, Jefferies KC, Panjwani N. Galectin-3 protein modulates cell surface expression and activation of vascular endothelial growth factor receptor 2 in human endothelial cells. J Biol Chem 2011; 286:29913-29921.
23. Nangia-Makker P, Balan V, Raz A. Regulation of tumor progression by extracellular galectin-3. Cancer Microenviron 2008; 1:43-51.
24. Delgado VM, Nugnes LG, Colombo LL, et al. Modulation of endothelial cell migration and angiogenesis: a novel function for the ẫtandem-repeat' lectin galectin-8. FASEB J 2011; 25:242-254.
25. Mathieu V, de Lassalle EM, Toelen J, et al.Galectin-1 in melanoma biology and related neo-angiogenesis processes. J Invest Dermatol 2012; 132:2245-2254.
26. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17:3835-3849.
27. Tripodo C, Sangaletti S, Piccaluga PP, et al. The bone marrow stroma in hematological neoplasms - a guilty bystander. Nat Rev Clin Oncol 2011; 8:456-466.
28. De Jong D, Fest T. The microenvironment in follicular lymphoma. Best Pract Res Clin Haematol 2011; 24:135-146.
29. Re D, Thomas RK, Behringer K, Diehl V. From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. Blood 2005; 105: 4553-4560.
30. Kanzler H, Hansmann ML, Kapp U, et al. Molecular single cell analysis demonstrates the derivation of a peripheral blood-derived cell line (L1236) from the Hodgkin/Reed-Sternberg cells of a Hodgkin's lymphoma patient. Blood 1996; 7:3429-3436.
31. Re D, Kuppers R, Diehl V. Molecular pathogenesis of Hodgkin's lymphoma. J Clin Oncol 2005; 23:6379-6386.
32. Gandhi MK, Moll G, Smith C, et al. Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma. Blood 2007; 110:1326-1329.
33. Rodig SJ, Ouyang J, Juszczynski P, et al. AP1-dependent galectin-1 expression delineates classical Hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features. Clin Cancer Res 2008; 14:3338-3344.
34. Suzuki O, Hirsch B, Abe M, et al. Galectin-1-mediated cell death is increased by CD30-induced signaling in anaplastic large cell lymphoma cells but not in Hodgkin lymphoma cells. Lab Invest 2012; 92:191-199.
35. Zacar?́as Fluck MF, Hess L, Salatino M, et al. The aggressiveness of murine lymphomas selected in vivo by growth rate correlates with galectin-1 expression and response to cyclophosphamide. Cancer Immunol Immunother 2012; 61:469-480.
36. Kamper P, Ludvigsen M, Bendix K, et al. Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma. Blood 2011; 117:6638-6649.
37. Ouyang J, Plutschow A, Pogge von Strandmann E, et al. Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma. Blood 2013; 121:3431-3433
38. Heslop HE. How I treat EBV lymphoproliferation. Blood 2009; 114:4002-4008.
39. Ouyang J, Juszczynski P, Rodig SJ, et al. Viral induction and targeted inhibition of galectin-1 in EBVÃ posttransplant lymphoproliferative disorders. Blood 2011; 117:4315-4322
40. Conconi A, Ponzio C, Lobetti-Bodoni C, et al. Incidence, risk factors and outcome of histological transformation in follicular lymphoma. Br J Haematol 2012; 157:188-196.
41. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8:68-74.
42. Hoyer KK, Pang M, Gui D, et al. An antiapoptotic role for galectin-3 in diffuse large B-cell lymphomas. Am J Pathol 2004; 164:893-902.
43. Clark MC, Pang M, Hsu DK, et al. Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death. Blood 2012; 120:4635-4644. This report identifies the phosphatase CD45 as the main counterreceptor for galectin-3 on DLBCL cells and presents evidence of the potential therapeutic use of galectin-3-specific inhibitors in this disease.
44. Demers M, Biron-Pain K, Hebert J, et al. Galectin-7 in lymphoma: elevated expression in human lymphoid malignancies and decreased lymphoma dissemination by antisense strategies in experimental model. Cancer Res 2007; 67:2824-2829.
45. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352:804-815.
46. Croci DO, Morande PE, Dergan-Dylon S, et al. Nurse-like cells control the activity of chronic lymphocytic leukemia B cells via galectin-1. Leukemia 2012. 10.1038/leu.2012.315. [Epub ahead of print]. This article highlights the role of galectin-1 expressed by nurse-like cells as a prosurvival and activating signal for CLL cells.
47. Gardner JM, Evans KG, Musiek A, et al. Update on treatment of cutaneous T-cell lymphoma. Curr Opin Oncol 2009; 21:131-137.
48. Papadavid E, Economidou J, Psarra A, et al. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sezary syndrome. Br J Dermatol 2003; 148:709-718.
49. Roberts AA, Amano M, Felten C, et al. Galectin-1-mediated apoptosis in mycosis fungoides: the roles of CD7 and cell surface glycosylation. Mod Pathol 2003; 16:543-551.
50. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. Am J Hematol 2012; 87:1037-1045.
51. Yamamoto-Sugitani M, Kuroda J, Ashihara E, et al. Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia. Proc Natl Acad Sci USA 2011; 108:17468-17473. The first description of galectin-3 as a prosurvival factor for CML.
52. O'Donnell MR, Appelbaum FR, Coutre SE, et al. Acute myeloid leukemia. J Natl Compr Canc Netw 2008; 6:962-993.
53. Cheng CL, Hou HA, Lee MC, et al. Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia. Blood 2013; 121:3172-3180
54. Ustun C, Miller JS, Munn DH, et al. Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood 2011; 118:5084-5095.
55. Zhou Q, Munger ME, Veenstra RG, et al. Coexpression of Tim-3 and PD-1 identifies a CD8Ã T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 2011; 117:4501-4510.
56. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364:1046-1060.
57. Streetly MJ, Maharaj L, Joel S, et al. GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death. Blood 2010; 115:3939-3948.
58. Mirandola L, Yu Y, Chui K, et al. Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma. PLoS ONE 2011; 6:e21811.
59. Abroun S, Otsuyama K, Shamsasenjan K, et al. Galectin-1 supports the survival of CD45RA(-) primary myeloma cells in vitro. Br J Haematol 2008; 142:754-765.
60. Kobayashi T, Kuroda J, Ashihara E, et al. Galectin-9 exhibits antimyeloma activity through JNK and p38 MAP kinase pathways. Leukemia 2010; 24:843-850.